Clinical Effects of Brain Machine Interface in Chronic Stroke Patient
NCT ID: NCT04451941
Last Updated: 2020-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2020-07-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RecoveriX with individual EEG calibration
RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
Experimental: RecoveriX with individual EEG calibration
RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
RecoveriX without individual EEG calibration
RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
RecoveriX without individual EEG calibration
RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental: RecoveriX with individual EEG calibration
RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
RecoveriX without individual EEG calibration
RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weak wrist extension
* Onset ≥ 6 months
* Fugl-Meyer Assessment score ≥ 19
* Cognitively intact enough to understand and follow the instructions from the investigator
Exclusion Criteria
* Severe upper extremity pain that could interfere with rehabilitation therapy
* Neurological disorders other than stroke that can cause motor deficits
* Uncontrolled severe medical conditions.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Rehabilitation Center, Seoul, Korea
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joon-Ho Shin
Chief of Brain Injury Rehabilitation Department, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joon-Ho Shin
Role: PRINCIPAL_INVESTIGATOR
National Rehabilitation Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Rehabilitation Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Joon-Ho Shin, MS
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NRC-2020-01-007
Identifier Type: -
Identifier Source: org_study_id